A panel from the FDA has backed Eli Lilly’s donanemab for its ability to slow the early progression of Alzheimer’s, paving the way for the treatment to be fully approved in the U.S. later in the year. NBC’s Dr. Tara Narula breaks down how the drug works on TODAY. NBC News Health
A panel from the FDA has backed Eli Lilly’s donanemab for its ability to slow the early progression of Alzheimer’s, paving the way for the treatment to be fully approved in the U.S. later in the year. NBC’s Dr. Tara Narula breaks down how the drug works on TODAY.
